Corvus Pharmaceuticals, Inc. (CRVS) Earnings Call Transcript & Summary

November 4, 2025

NASDAQ US Health Care Biotechnology earnings 42 min

Earnings Call Speaker Segments

Zack Kubow

executive
#1

Thanks a lot, Operator, and good afternoon to all of you. We appreciate you being with us for Corvus Pharmaceuticals' Third Quarter 2025 Business Update and Financial Results Conference Call. Here to talk through the results and business updates are Richard Miller, our Chief Executive Officer, Leiv Lea, our Chief Financial Officer, Jeff Arcara, our Chief Business Officer, and Ben Jones, Senior Vice President of Regulatory and Pharmaceutical Sciences. The executive team will kick things off with some prepared remarks, and after that we'll move into a question-and-answer period. I want to remind everybody that the comments management makes today, along with responses to questions, will contain forward-looking statements. Such statements rest on estimates and assumptions as of today and carry risks and uncertainties that could lead actual results to differ materially from what those statements express or imply, including the risks and uncertainties laid out in Corvus's quarterly report on Form 10Q for the quarter ended September 30, 2025, as well as other filings the company makes with the SEC from time to time. Except as required by law, the company assumes no obligation to publicly update or revise any forward-looking statements. With that said, I'd like to hand the call over to Leiv Lea. Leiv?

Leiv Lea

executive
#2

Thanks, Zack. I'll kick things off with a quick look at how we did financially in the Third Quarter of 2025, and after that I'll hand things over to Richard so he can walk you through the business side. R&D spending for the Third Quarter of 2025 came to $8.5 million, which is up against the $5.2 million we recorded during the same stretch of 2024. That $3.3 million bump was driven mainly by greater costs for clinical trials and manufacturing tied to developing Soquelitinib, along with higher personnel-related expenses. Our net loss in the Third Quarter of 2025 landed at $10.2 million, and that figure includes a $300,000 non-cash loss connected to Angel Pharmaceuticals, our partner in China. For comparison, the net loss in the same period of 2024 stood at $40.2 million, a number that reflected a $32.8 million non-cash loss from the change in fair value of Corvus's warrant liability plus a $700,000 non-cash loss tied to Angel Pharmaceuticals. Total stock compensation expense for the Third Quarter of 2025 reached $1.2 million, versus $700,000 during the equivalent period in 2024. At September 30, 2025, Corvus held cash, cash equivalents, and marketable securities amounting to $65.7 million, compared with $52 million as of December 31, 2024. Just like we said last quarter, we anticipate that the cash we currently have will keep operations funded through the Fourth Quarter of 2026. At this point I'll pass the call to Richard, who will go over our clinical progress and give more detail on our strategy and plans.

Richard Miller

executive
#3

Thanks, Leiv, and hello, everyone — appreciate you tuning in for today's update. Getting Soquelitinib further along in atopic dermatitis and T-cell lymphomas remains our number one priority, and there are multiple key milestones on the horizon for these programs. To begin, enrollment is now complete for the extension cohort 4 portion of our phase I trial, and we anticipate having the full dataset in hand by late December. Because that timing falls during the holiday period, our intention is to report the findings in January. Next, we continue to expect our phase II atopic dermatitis trial to launch in early Q1 2026. We believe Soquelitinib is well positioned—it's an oral treatment with a new mechanism of action, and so far it has shown a good safety and efficacy profile. There's been rising interest in drugs that work through novel mechanisms for atopic dermatitis and other inflammatory conditions. Our confidence in Soquelitinib is strengthened because we think the data we've produced to date not only stacks up well against recent datasets from other approaches, but also points to the possibility that we could lead in this space. We're also feeling positive because the clinical results gathered to date for Soquelitinib, covering both atopic dermatitis and T-cell lymphoma, support the notion that blocking ITK may prove effective across a broad range of immunology and inflammatory conditions, and we're still exploring which additional opportunities our platform could pursue going forward. During today's call, I'll go over extension cohort 4, explain our reporting plans for that data, and give an update on where the phase II study we've scheduled in atopic dermatitis currently stands. I'd also like to cover the reasons the Soquelitinib oral presentation at ASH matters for our phase III trial in peripheral T-cell lymphoma, what it hints at for immune and inflammatory indications — including atopic dermatitis — and after that, I'll briefly go over other operational progress and updates. To begin, let me take everyone through the key results on Soquelitinib in atopic dermatitis that we've reported so far. In June, we released findings from cohort 3 of the phase I study, which evaluated a 200 milligram oral dose given twice daily over 28 days of treatment, and that came on the heels of the positive data we'd already announced at a lower dose from cohorts 1 and 2. Looking at every treatment arm, both safety and efficacy compared favorably with placebo. The most notable finding involved cohort 3, in which responses arrived earlier and proved deeper relative to cohorts 1 and 2. When day 28 arrived, the mean EASI score reduction in cohort 3 reached 64.8%, versus 54.6% across cohorts 1 and 2 combined and 34% for placebo. Within cohort 3, half of the patients reached EASI 75, 8% reached EASI 90, and 25% reached IGA 0 or 1. Among placebo recipients, none reached EASI 75 or IGA 0 or 1. Itch was affected as well — many patients in cohort 3 described sharp decreases in their PP-NRS scores as reported by patients, starting on day 8. As for the speed at which responses appeared, Cohort 3 pulled ahead of placebo earlier and more strongly than Cohorts 1 and 2 did, with the split starting on day 8, and EASI score gains continued to accumulate at day 15 and day 28. That trajectory is still heading lower, suggesting that a longer course of treatment could produce even deeper responses — which is what we're looking into right now with Extension Cohort 4. Enrollment is now complete in that extension cohort of the phase I study, which is testing 24 patients at the 200-milligram twice-daily dose used in Cohort 3, administered over 8 weeks, followed by another 30 days of follow-up with no treatment. In that group, there were 24 patients, and they were randomized in a blinded manner, one-to-one, against placebo — so 12 received the active drug and 12 received placebo. As we've mentioned previously, our plan is to share the 8-week data set for those 24 patients in January. The purpose of gathering this additional data is to confirm what we observed in the earlier cohorts, but in a larger group of patients, and to determine if efficacy is stronger when treatment lasts the longer 8-week period. Regarding Soquelitinib in atopic dermatitis, the next milestone on the horizon is launching the phase II clinical trial we've been planning, which we anticipate beginning in early Q1 2026. This will be a double-blinded, placebo-controlled, randomized study, taking place at approximately 70 sites globally. The trial aims to bring in around 200 subjects suffering from moderate to severe atopic dermatitis who haven't had success with at least one topical or systemic treatment previously. I'd like to emphasize that individuals who have not responded to systemic therapies such as Dupixent or JAK inhibitors are also being included. Our interest in this group stems from the fact that Soquelitinib works differently than drugs that are currently available, so prior use of those treatments shouldn't lead to resistance against Soquelitinib. There are four groups in this study, and participants will be divided equally among them. Each group of 50 will receive either Soquelitinib at 200 milligrams taken once a day, 200 milligrams taken twice a day, 400 milligrams taken once a day, or a placebo. The treatment period runs for 12 weeks, after which participants enter a 90-day follow-up phase with no therapy. The main measure the trial is designed around is how much the EASI score drops on average, expressed as a percentage, comparing the starting point to week 12 — this is the accepted endpoint for phase II studies in atopic dermatitis. For the secondary endpoints, we'll be looking at the percentage of patients who reach EASI 75 or an IGA of 0 or 1 by week 12, plus how the treatment affects itching, which we'll measure by the share of patients seeing a drop of at least 4 points on the PP-NRS at week 12, along with safety. As part of the study, we need photographs showing the disease at baseline and how it responds to therapy, and independent experts will review those images. Turning to oncology, enrollment is ongoing for our registrational phase III study of Soquelitinib in relapsed PTCL, and we're aiming for interim data toward the end of 2026. We're also happy to share that the complete findings from our phase I-b study of Soquelitinib in relapsed refractory T-cell lymphomas are going to be shared during an oral session at the American Society of Hematology's annual meeting in December; that talk will cover the clinical data along with the supporting preclinical work that pushes us to keep moving the program forward for PTCL, and it will also lay out the rationale and safety information that leads us to concentrate on immune and inflammatory diseases; specifically, we'll share data on how long progression-free survival and overall survival last. From our perspective, the data presented at ASH reinforces an accumulating body of clinical evidence. This shows that Soquelitinib has a solid safety and efficacy profile, and that the way it works gives it potential value in T-cell lymphoma as well as in diseases where the immune system is the driver. As a quick recap: certain people enrolled in the phase 1 trial stayed on treatment past the two-year mark, taking the same daily dose range that is now being explored for atopic dermatitis. On top of that, some patients whose tumors were highly aggressive saw their tumors disappear completely, with those responses lasting. At the same time, preclinical evidence keeps building, strengthening the argument that blocking ITK may be helpful in a much wider set of indications — dermatology, rheumatology, pulmonary medicine, solid cancers, and others among them. Turning briefly to other operational updates: in October, we brought on Mr. We'd like to extend a welcome to David Moore, who came onto the board in April together with Richard van den Broek. David serves at Novo Nordisk as both Executive Vice President US Operations and President. He's been at the helm of a GLP-1 franchise that ranks among the most successful, and his extensive expertise spanning strategy, commercial, market access, business development, and investing ought to be a key strategic resource for us as we pursue the complete potential of our ITK inhibitor platform. To wrap up, we continue to feel very enthusiastic about what Soquelitinib could achieve in atopic dermatitis. On top of that, what we're learning from the study now underway is leading us to consider a wide range of other immune diseases beyond atopic dermatitis. There's a chance that blocking ITK in a targeted way might turn into a new way to treat autoimmune inflammatory conditions, with the approach centered on modifying or rebalancing cellular immunity. Updates on Soquelitinib are something we're eager to provide in the months ahead, starting with ASH for the T-cell lymphoma program, followed in January by data from Extension Cohort 4 in the atopic dermatitis program. Along with the phase 2 atopic dermatitis trial we plan to begin in early Q1 2026 and the phase 3 PTCL trial that continues to enroll, momentum behind Soquelitinib is growing considerably as we move into the new year. With that, I'll hand things over to the operator so we can begin the question-and-answer session. Operator.

Graig Suvannavejh

analyst
#4

I appreciate you answering my questions, and well done on the quarter's advances. A few things I wanted to ask. To start, regarding your ASH abstract and the results you're going to share next month — what struck me was how strong the OS data looked. Given that, along with the other details contained in the abstract, might you frame for us the comparability that clearly underlies your excitement about Soquelitinib's prospects in peripheral T-cell lymphoma? Thanks. I'll follow up with my second question afterward.

Richard Miller

executive
#5

Graig, thanks for asking. To begin, the PFS and OS data set to be shown at the ASH meeting are really quite striking. That's particularly true when you factor in that this is a phase I study of an agent never before evaluated in this disease. As everyone here knows, T-cell lymphoma is a dreadful illness, and upon relapse the median survival tends to run roughly six months. Our outcomes are much better than that, and that has us enthusiastic. Another source of our enthusiasm is how much this trial has taught us about immunobiology, safety, pharmacokinetics, pharmacodynamics, and mechanisms of action — all of which are highly relevant to immune diseases. Something I discuss in the ASH abstract, and will expand upon during the meeting, is that we are observing responses in T-cell lymphomas that are what's called GATA3 positive. Now, GATA3 is a transcription factor also recognized as the master regulator of Th2 function. Th2 cells are the cells of interest across a variety of immune diseases, atopic dermatitis among them. So when you bring all of that together, we believe it's a good sign, not only for the T-cell lymphoma program but also for a range of immune diseases; it confirms and aligns with our conviction that we have a drug with a truly novel mechanism of action. It's oral. It appears very safe. And we are seeing truly meaningful signals of activity in patients whose cancer of the immune system involves the very same cells implicated in all these other immune diseases. I hope that answers your question.

Graig Suvannavejh

analyst
#6

You certainly did. Thanks a lot. Now, if we could turn to Soquelitinib and the atopic dermatitis data readout you've got coming early in the year. Given that you've lengthened how long patients are treated and increased how many patients are enrolled, can we reasonably assume that what you observed before will translate into better efficacy than what you saw? And should there be no improvement relative to the earlier results, does that alter your enthusiasm at all regarding the prospects for Soquelitinib in atopic dermatitis?

Richard Miller

executive
#7

Appreciate the question. Well, to begin with, our view — and the view of a number of outside experts too — is that the data we produced in Cohort 3 with 28 days of treatment was pretty strong. It was safe, and it was quite active in that. What we're aiming to demonstrate — and as you'll remember, the reduction in EASI scores kept continuing downward through the final few weeks of therapy — so with the larger cohort, we're really after two things. First, we want to demonstrate consistency. We want to demonstrate, confirm what we demonstrated earlier in a bigger group of patients with more placebos and more patients receiving active drug. Placebos, I don't need to remind you folks, placebos matter a great deal when evaluating these diseases. The second thing we're after is whether extending the treatment duration pushes the results even further. So those two concepts — I want to see consistency in the data versus what we did earlier; and yes, we'd like to see an improvement as we go past 28 days; and naturally, we want to confirm safety and the other things as well; so that's what to expect as we look at the data that comes out in January.

Graig Suvannavejh

analyst
#8

Really appreciate it, and I'll get back in line.

Richard Miller

executive
#9

Hello there, everyone. Am I coming through? Indeed.

Jeff Jones

analyst
#10

Excellent. I appreciate you taking my question. Also, congratulations on the genuine advancement you're achieving. First, regarding Soquelitinib. Richard, like you said, you've observed and been producing data plus several other indications within the INI space. At this stage, what are your intentions for advancing Soquelitinib into additional indications, meaning which indications and what timing?

Richard Miller

executive
#11

All right. Let me clarify, Jeff. In people, Soquelitinib is under investigation in the registration phase III study and, naturally, in our phase I atopic dermatitis study. There's also a study in a lymphoproliferative disease known as ALPS, which you're aware of. At this point, we've assessed Soquelitinib across numerous preclinical models, ranging from asthma, atopic dermatitis, psoriasis, scleroderma, systemic sclerosis, and so on. We're formulating concrete strategies to expand into additional immune-related diseases. I'll share further details on that early next year. Currently, asthma appears to be a key disease for us, along with likely another dermatologic condition that hasn't been determined yet.

Jeff Jones

analyst
#12

Great. Thank you for that. The Kidney Cancer Research Consortium then provided an update at ASH regarding the ciforadenant trial. I'm just wondering what comes next. That study hasn't finished yet. Some participants remain in follow-up. How do you view ciforadenant when it comes to renal cell and other areas?

Richard Miller

executive
#13

So Ciforadenant, as you're aware, that study was run together with the Kidney Cancer Research Consortium, and they covered the bulk of its costs. I believe we don't have additional expenses tied to it. 19 people were still receiving treatment and being followed, 19 of 50, roughly 40% almost. So we'll keep tracking those individuals, and once we observe how the remaining data develops, we'll determine our next move. That said, that's what we're planning right now for it.

Jeff Jones

analyst
#14

Okay. I’ll get back in line. The next person to ask a question is Li Watsek with Cantor. Please go ahead. Hi, everyone. Nice work on the progress. I have two questions. First, regarding the baseline traits for cohort 4 compared with the earlier three cohorts, should we think they are fairly close to cohort 3, or is there something different we ought to note? And I have one more question after that.

Richard Miller

executive
#15

It is quite fair for you to think those traits are much like cohort 3. To say more about that: 17 centers are enrolling in the trial, and every one is in the US.

Li Watsek

analyst
#16

The identical sites used across the initial 3 cohorts. No eligibility requirements have been altered. And indeed, we already know what our patients' demographics look like. Extremely, extremely close to cohort 3. Okay. Great. And after that, regarding the phase 2 trial, considering the population you'll be enrolling, it sounds as though these patients may have had exposure to JAK inhibitors and DOP; so considering this demographic. What ought the bar to be for the EASI score?

Richard Miller

executive
#17

Oh. Okay. So to start with. Once we move into phase 2, naturally, that's a bigger study, 200 patients. Enrolling that entirely within the US would prove quite hard and take quite a while. Therefore, there will be substantial dependence on sites beyond the United States, especially across Europe, which is what the majority of companies do these days. I believe we're rather distinctive in permitting patients who've failed DOP and JAK along with other systemic treatments within reason. I mean, failing 10 therapies isn't something you can do. But; the rationale behind this approach is that certain patients we've observed in cohorts 1, 2, 3, and by now even within the fourth cohort, who've failed those systemic treatments, are responding to our drug. So. I don't yet know what the eventual figures will look like on this. Whether it matches first-line therapies exactly or doesn't quite match. So it's somewhat difficult for me to state what that bar is. To begin with, I'm not conscious of any data published specifically regarding how a drug responds in someone who's failed a JAK inhibitor or DOP. Now, such studies do, as I understand it, reuse patients. They enroll patients who are EASI 50s, then treat them once more across extended periods; yet that's genuinely a separate sort of experiment. So look, I think it's somewhat premature to establish a bar for the phase II. Let's obtain our phase I results. Let's examine the Dupixent failures along with the JAK failures, and afterward we can discuss that further. But I think this is a significant point. I'm happy you posed the question that the Corvus patient population differs somewhat. Now, we're doing this on purpose; we want these failures since we believe we possess a drug whose mechanism of action will go where the resistance mechanism to a Dupixent or a JAK might not actually be pertinent or relevant for our mechanism. And then we must learn that. So the encouraging news here is that it broadens the potential application of our drug. We sense that it potentially might be used first-line, or it might be used in the relapse situation. Okay?

Li Watsek

analyst
#18

Thanks. Yeah, thanks a lot.

Aydin Huseynov

analyst
#19

Hello there, and good afternoon. Congratulations on what you achieved during this quarter, and we appreciate you fielding our questions. I have a few, so Richard. You already have an atopic dermatitis study underway, and I was wondering if you could share any perspective regarding possible additional skin-related conditions, for instance hidradenitis suppurativa, vitiligo, psoriasis, or something beyond those; and is it feasible to conduct multiple studies at the same time, multiple dermatology studies at once? I simply wanted to hear your perspective regarding that.

Richard Miller

executive
#20

All right. Well, the animal models plus the findings generated in our laboratory indicate that asthma ought to be a really strong target for us. We additionally believe a condition such as hidradenitis suppurativa would be an excellent condition for us; it falls within dermatology, and that condition is driven by both Th2 and Th17; so let's consider that for a moment. A Dupixent, say, or a STAT6 inhibitor or something similar will capture your Th2-type cytokines, yet it won't capture TH17 since that doesn't signal via STAT6. Thus we believe we hold a clear edge in this case for a condition such as HS since we target both TH17 and Th2. There are additional factors too; so, other conditions under consideration include prurigo nodularis. That one is a Th2 and TH17 condition too. It isn't as prevalent, yet the unmet need is even greater in that case. Alopecia areata, we have looked at. It's an extremely crowded space. JAK inhibitors perform well, yet it remains on our list, and we continue doing some work there. Now, regarding your question, is it possible to conduct additional studies? We plan to conduct numerous studies in immune disease. We plan to advance this drug across numerous areas, as I said during my talk, not only dermatology, pulmonary medicine, oncology, rheumatology, and so on; now, naturally, we recognize that at some point, we will need to bring in additional capital to accomplish that; and we're hopeful that given the data we have forthcoming; we will be able to bring in capital to support those efforts.

Aydin Huseynov

analyst
#21

Thanks. That's really useful, Richard. I have another question about the phase 2 registration trial. I was hoping to get a clearer picture of the schedule, when we might see data, and ideally when the drug could reach the market. With everything happening around Soquelitinib, I assume this is the first indication. That's the first indication where we'll launch the drug. I just wanted a better sense of the near-term commercial opportunity and the timelines in PTCL for Soquelitinib.

Richard Miller

executive
#22

Yeah; so, our timeline involves a futility interim analysis at the end of 2026. We'll probably have the full data set completed by the end of 2027. Launch, I believe, would come relatively quickly for this. A nice feature of this study is that it's a single registration randomized trial that could result in full approval if you hit your endpoints; and it involves 150 patients, a fairly small trial with fairly short endpoints. The chemotherapy control arm is expected to have a median PFS, which is the primary endpoint, of, what, three months, two months. So we're excited about it. I'm an oncologist, and lymphoma is my area of expertise, as you know. And I ran a clinic at Stanford for 25 years or more treating lymphoma patients. There's no treatment, no good treatment for this disease. There's no competition at this point, even in the research stages. I mean, really, there's nothing new in this area; so we think that we think we have the potential. If this drug gets approved, it would be used immediately in all T-cell lymphomas, front-line, late-line, you name it, because really, there isn't anything else. I mean, we have a ways to go before we can figure all that out. But the opportunity here, we think, is much larger than people recognize. Now, it's not atopic dermatitis; in terms of the number of patients, of course, but it also doesn't have the competition, and it also doesn't have the very long timelines to approval. All right?

Aydin Huseynov

analyst
#23

Got it. Thank you very much. I appreciate you taking the questions, and congratulations on the progress.

Jordan Becker

analyst
#24

Hello. Jordan Becker here, filling in for Etzer Darout. Thanks for fielding our questions, and congrats on the updates. I have two questions. You touched on this, but I just want to dig into it further. Are there plans for any post hoc analysis once the cohort completes, to examine efficacy among Dupixent and JAK naive and refractory populations? And second, can we look forward to a similar analysis regarding biomarker correlates of clinical efficacy with the updated data?

Richard Miller

executive
#25

Yes and yes, Jordan. Thanks for asking. We will, naturally, be conducting post hoc analysis attempting to determine how the drug works, how to improve its performance, all sorts of things. So obviously, examining the impact of prior therapy, prior systemic therapies, all those clinical variables will be assessed. We have a fairly aggressive biomarker program. We're keeping biopsies of patient lesions to a minimum, simply because that hurts enrollment, and we don't want that; however, we now have a fairly extensive program examining single-cell RNA sequencing of blood. And that's uncovering a lot of interesting things. I mean, many new things are emerging on this. I think the same old, same old, looking at IL-13 or whatever. That's going to go bye-bye, TARC, etc. Those aren't good biomarkers. Everyone knows that. The best biomarkers for these diseases have yet to be defined, since they're heterogeneous diseases, and we don't really know what the cause is. So we're examining a lot of that. We'll report on what we find. The biomarker game is a tough game. There are a lot of variables to examine and it's hard to make much of anything when you have a small number of patients; but we certainly will hope to get clues. And signals that we can validate in larger trials. Okay?

Jordan Becker

analyst
#26

Fantastic. Thanks once more, and congratulations on the recent updates.

Sean Lee

analyst
#27

Hi there. Good afternoon, everyone, and I appreciate you fielding my questions. I've got just a few brief ones regarding how the upcoming phase II AD study is designed; so. What's the rationale for choosing a treatment period of 12 weeks instead of the 8-week one being tested in Cohort 4? And do any meaningful distinctions exist in the enrollment criteria for the phase II versus. The individuals being enrolled in phase I? Thanks.

Richard Miller

executive
#28

Up to this point, the eligibility criteria are essentially the same. The rationale for moving to 12 weeks is that we intend to look into that. Nowadays most therapies go out to 16 weeks. However, when you examine the data across most trials, you'll notice that the bulk of the separation, the bulk of the efficacy, is achieved within the initial 12 weeks. Treating for a longer period doesn't truly deliver much additional benefit. That's why we chose a 12-week study. Look, my aim is to make this treatment shorter, not lengthier. Okay? I'm not aware of any patient. And as I said before, I've been operating a clinic for more than 30 years. I'm not aware of any patient who wants additional medicine to take for a longer time. So. I'm attempting to determine whether we can make it shorter, not lengthier. But naturally, we want to maximize both, and both matter. You want to maximize responses. You want to ideally aim for complete elimination of disease; that part is easy. 100% is the goal. And. That's what we'll endeavor to achieve. But when you examine most trials. Moving from 12 weeks to 16 weeks doesn't add much. Now, certain people are going to 6 months, 1 year. I mean. Wonderful. If you're prepared to take a drug for that duration for an incremental benefit, that's marginal.

Sean Lee

analyst
#29

I appreciate the extra detail. That really helps.

Cha Cha Yang

analyst
#30

Hello, Cha Cha Yang here, standing in for Roger Song. Many thanks for hosting this call, and we appreciate you addressing our question. I was wondering whether you might share some insight regarding any strategies you have around possible collaborations or licensing arrangements involving Soquelitinib down the road, or alternatively, whether your intention is to secure financing and advance this on your own in both AD and oncology. Thanks.

Richard Miller

executive
#31

All right, thank you for asking that, Cha Cha. What I can share is that ITK, when viewed as a target, has drawn attention from essentially every large player active in this space. My confidence in that comes from the conversations we are having with them. Whenever partnering possibilities emerge, we will assess them. That applies whether in oncology or in immune diseases. Right now, though, we are continuing to move our cancer program and our immunology program ahead. As I said a short while back, we understand clearly that additional capital will be necessary if we are to develop all of these programs to their fullest. Our data gives us reason for optimism, and we believe there will be plenty of chances to bring in funding, whether by issuing shares or through partnerships when the timing is right.

Cha Cha Yang

analyst
#32

Alright. I appreciate that.

Graig Suvannavejh

analyst
#33

Our next question comes from Graig Suvannavejh at Mizuho. Go right ahead. Oh, thank you for taking the follow-up. I found myself quite curious — when you consider the ITK portfolio and what you've said about possibly moving next-generation ITKs ahead — I wanted to ask, Richard, whether you might describe the vision or the strategy regarding the possibility of pursuing an additional indication for Soquelitinib, as opposed to taking a next-generation ITK inhibitor forward, maybe with a comparable indication in mind. How exactly do you weigh that type of strategy?

Richard Miller

executive
#34

Thank you. Well. I appreciate the question. That's a solid question. Clearly, moving Soquelitinib forward — which by now has a rich body of safety and efficacy data across hundreds of patients — will happen more quickly than developing one of our backup compounds, which, naturally, still must complete IND enabling studies. And beyond that, within the immunology space, keep in mind that normal volunteer, single-dose as well as normal volunteer, multi-dose work is required. So time is involved there. Still, all of that is something we intend to weigh. At present, we're advancing in PTCL, atopic dermatitis, and before long additional immune diseases. Other dosage forms and formulations of Soquelitinib are also under consideration as well. That work is ongoing right now. In addition, we're examining Soquelitinib-like ITK degraders. Some of those have been made by us. In the laboratory, we're evaluating them. What's interesting is that Soquelitinib, being a covalent drug, actually causes the ITK target to degrade to some degree. That's something we've come to learn. It's genuinely fascinating. My sense is nobody has been aware of that previously. So any and all of that is being explored by us, though without question, moving our lead compound ahead at this point will be the quickest path.

Graig Suvannavejh

analyst
#35

All right. I appreciate you explaining that.

Jeff Jones

analyst
#36

Hi. Thanks, everyone, for letting me ask a follow-up. This will be brief. I'd like to go a bit further into the Dupixent and JAK-exposed individuals who might be able to join the phase 2 trial. Will you be designing the trial with enough statistical power to conduct a subgroup analysis that could once again reach statistical significance and distinguish those patients with prior systemic exposure from those who are systemic therapy naive?

Richard Miller

executive
#37

No. That isn't something we'd do. I mean. At this point, Jeff, we lack sufficient information to make that kind of commitment. One thing I can say for certain, though, is that we will stratify the trial so that subgroup can be examined. To clarify what I mean, that will be the fine subgroup. Randomization will be stratified according to whether a patient previously failed a systemic therapy or did not. You want those patients evenly spread across your placebo and your active arm. But since we don't truly know the efficacy signal we'd anticipate there yet, it's somewhat difficult to power how many patients would be required and what effect you're chasing. I believe that would be pushing things quite far. I doubt you'd want to take that approach at this point. My preference would be to run a trial, include everybody. The ideal result, run a trial, include those patients, achieve a positive trial on your predefined endpoint. You secure approval. I mean, or phase 3, you secure approval for everybody.

Jeff Jones

analyst
#38

Yes, absolutely. That's wonderful. And stratifying would be another angle from which to consider it; I truly value how clear that was.

Richard Miller

executive
#39

Thank you, Jeff.

Richard Miller

executive
#40

Sir, you have the floor. Many thanks, operator. I appreciate all of you joining us on this call. We're eager to keep moving the Soquelitinib programs forward along with our other programs, and we're eager to bring you updates on how those efforts are progressing as we head into 2026 and past that point. Thanks so much.

Operator

operator
#41

Everyone, that brings us to the end of today's conference call. We appreciate all of you joining us. At this point, you're free to hang up.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Corvus Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Corvus Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Corvus Pharmaceuticals, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.